Regional metastatic differentiated thyroid cancer (mDTC) provides a unique model in which to study the tumorimmune interface. These lymph node metastases persist for years, generally without progression to distant metastases. Although the immune system likely impedes disease progression, it is unsuccessful in eliminating disease. Our previous studies revealed that programmed death-1 (PD-1) þ T cells were enriched in tumor-involved lymph nodes (TILN). Tumor-associated leukocytes and tumor cells were collected from grossly involved lymph nodes from 12 patients to further characterize the phenotype and functional potential of mDTC-
Introduction
More than 500,000 people in the United States have a diagnosis of thyroid cancer, and the incidence is steadily growing, with an estimated 62,000 new cases in 2014 (1) . Although localized differentiated thyroid cancer (DTC) is generally managed by surgery and radioactive iodine therapy, approximately 10% of patients develop progressive invasive primary disease and 5% develop distant metastases (1) . Twenty percent to 30% of patients with DTC develop persistent or recurrent disease, most commonly in locoregional lymph nodes, requiring additional surgical intervention with increased morbidity and expense (2) . Patients with aggressive DTC that are resistant to standard treatments may be excellent candidates for innovative adjuvant therapies, including immunomodulating approaches.
DTC provides a unique model in which to study the interplay between the immune response and the metastatic tumor. Lymph node metastases are common in patients with DTC (>60%; ref. 3 ). These regional metastases are thought to persist for years, generally without progression to distant metastasis. The 5-year survival rate for these patients is 97.4%, only slightly reduced compared with the 99.9% survival rate observed in patients with localized disease. In contrast, regional lymph node involvement in patients with lung, melanoma, or breast cancer indicates a significantly reduced rate of survival compared with localized disease (53.5% to 26.1%, 98.3% to 62.4%, and 98.6% to 84.4%, respectively; ref. 1) . Despite their presumed indolent nature, DTC metastases are not eliminated by the immune system, suggesting that the immune response may be compromised. In support of this theory, our previous studies revealed that regulatory T cells (Treg) and programmed death-1 (PD- 1) þ T cells are elevated in tumorinvolved lymph nodes (TILN) and may contribute to disease severity and recurrence (4) . T-cell exhaustion, which was originally described in models of chronic viral infections, is now established as an important mechanism of immune evasion in cancer. Exhausted T cells are characterized by the sustained expression of one or more inhibitory molecule [e.g., PD-1, cytotoxic T-lymphocyte antigen-4 (CTLA-4), and T-cell immunoglobulin and mucin domain 3 (Tim-3)]. These cells become increasingly dysfunctional during chronic antigen exposure, with loss of IL2 production and reduced ex vivo proliferative and cytotoxic potential preceding the loss of TNFa and IFNg production. Exhaustion culminates in deletion by apoptosis (5, 6) . Exhausted CD8 þ T cells display a unique expression pattern of activation markers and cytokine receptors (7) . For example, these cells fail to downregulate CD27, which is normally reduced upon T-cell activation. Furthermore, exhausted T cells maintain reduced levels of CD127, which is required for the survival of normal memory T cells. Varied degrees of CD8 þ T-cell exhaustion have been reported in melanoma, ovarian cancer, lymphoma, chronic lymphocytic leukemia (CLL), and non-small cell lung cancer (NSCLC; refs. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Coexpression of inhibitory receptors has been associated with a higher degree of dysfunction in both viral and tumor models (10, 18) . PD-1 and Tim-3 coexpression marked the most dysfunctional tumorspecific T-cell subset in peripheral blood of patients with melanoma (10) . Although CD4 þ T-cell exhaustion has not been thoroughly characterized in human cancers, studies in mouse models of chronic viral infection and patients infected with HIV suggest that virus-specific CD4 þ cells express multiple inhibitory receptors and are compromised in their ability to produce effector cytokines (19) (20) (21) (22) . Similar to CD8 þ T cells, CD4 þ T-cell exhaustion is characterized by sustained CD27 expression and downregulation of CD127 (20) . A recent study using a mouse model of recurrent melanoma revealed that tumor-specific CD4 þ T cells expressed multiple inhibitory receptors, including PD-1 and Tim-3 (23) . In patients with B-cell lymphoma, tumor-associated CD4 þ T cells expressed PD-1 and Tim-3 and displayed reduced capacity for proliferation and cytokine production (17) .
In our previous studies, we sampled both uninvolved lymph nodes (UILN) and TILNs from patients with DTC by fine-needle aspirate biopsy to characterize the T-cell milieu (4). Tregs were enriched in TILNs compared with UILNs, and increased levels were associated with recurrent disease. Furthermore, PD-1 þ cells were enriched in both CD4 þ and CD8 þ T-cell subsets in TILNs compared with UILNs and were associated with extranodal invasion. PD-1 þ CD4 þ and CD8 þ T cells were antigen-experienced memory cells that maintained the ability to produce IFNg following stimulation with phorbol-12-myristate-13-acetate (PMA) and ionomycin, but failed to fully downregulate CD27. To further investigate the role of PD-1 and T-cell exhaustion in metastatic DTC (mDTC), we characterized the phenotype and functional capacity of tumor-associated lymphocytes recovered from TILN tissue sections. These studies are the first to investigate CD4 þ and CD8 þ T-cell functional exhaustion in thyroid cancer.
Materials and Methods

Patients and histopathologic parameters
Patients with thyroid cancer undergoing surgical neck dissection for primary or recurrent disease at the University of Colorado Hospital between 2012 and 2014 were offered enrollment in this Institutional Review Board-approved study. Twelve patients were enrolled for the study and were confirmed by histopathology or previous medical reports to have conventional papillary thyroid cancer (PTC; patients 2-9), follicular variants (patient 10), or diffuse sclerosing variants (patients 1, 11, and 12). Chronic lymphocytic thyroiditis was evident in patients 1, 2, and 12. Each case was retrospectively assessed for lymph node involvement, size of metastases, and extranodal extension. Three normal lymph nodes from trauma patients were acquired from the National Disease Research Interchange. An archived normal lymph node from a patient with no history of cancer or autoimmune disease was used as a control for immunohistochemistry.
Sample acquisition and processing
Lymph nodes ranged from 1.5 to 2.9 cm in greatest diameter and housed visible tumor parenchyma. Each TILN was bisected, and an interior tissue section was donated. Multiple nodes were sampled when available to increase yield. Samples were collected in Hanks balanced salt solution (HBSS) and digested with 2.5 mg/mL Liberase DL and 10,000 U/mL DNase I (Roche) at 37 C for 1 hour. Red blood cells were lysed [37 C for 5 minutes; 150 mmol/L ammonium chloride, 10 mmol/L potassium bicarbonate, and 0.1 mmol/L ethylenediaminetetraacetic acid disodium salt dehydrate (EDTA)], and the remaining cells were incubated overnight in media [RPMI1640 (Gibco), 10% heatinactivated HI-FBS, 1:500 penicillin/streptomycin (Gibco)]. Nonadherent cells (enriched for lymphocytes) were harvested and adherent cells (enriched for tumor cells) were trypsinized (0.25% Trypsin-EDTA; Gibco). Cells were cryopreserved in freezing media [10% dimethyl sulfoxide (DMSO) in HI-FBS at 1-10 Â 10 6 cells/ mL]. Sample size and tumor/lymphoid composition varied; thus, a complete phenotypic and functional analysis was not attainable for all samples. Normal or patient-matched peripheral blood was donated for isolation of mononuclear cells (PBMC) using Lymphoprep gradient media (Axis-Shield PoC AS). Normal lymph nodes were manually disaggregated to obtain a single-cell suspension. Peripheral blood and normal lymph nodes were cryopreserved as described above. Cryopreserved cells were thawed within 6 months of freezing.
Antibodies
Anti-CD3-AlexaFluor700 (UCHT1), anti-CD4-APC-eFluor480 (RPA-T4), anti-CD69-biotin (FN50), anti-CD127-PerCP-Cy5.5 (eBioRDRS), anti-CD27-APC-eFluor780 (LG.7F9), anti-CD4-FITC (RPA-T4), anti-CD27-PE-Cy7 (LG.7F9), anti-CD45-APC (2D1), and anti-EpCAM-PE (IB7), anti-FoxP3-PE-Cy7 (PCH101), anti-IL2-PE-Cy7 (MQ1-17H12), anti-IFNg-APC-eFluor780 (4S. B3), anti-TNFa-PerCP-Cy5.5 (Mab11), anti-PD-1-APC (MIH4), anti-PD-L1-PE-Cy7 (MIH1), mIgG1k-PE-Cy7 (P3.6.2.8.1), anti-CD45RA-FITC (HI100), anti-CD45RO-biotin (UCHL1), CD62L-PE-Cy7 (DREG-56), CCR7-APC-efl780 (3D12), anti-CD3 (OKT3), and anti-CD28 (CD28.2) were purchased from eBioscience. Anti-CD8-BV510 (RPA-T8) was purchased from BioLegend. Anti-CTLA-4-Biotin and anti-Ki67-PerCP-Cy5.5 (B56) were purchased from BD Biosciences. Anti-TIM-3-PE (344823) was purchased from R&D Systems. Anti-LAG-3-FITC (17B4) was purchased from Enzo Life Sciences International, Inc.. Anti-CD107a-PE-Cy7 (H4A3) and anti-perforin-PerCP-Cy5.5 (dG9) were purchased from BD Biosciences. Anti-galectin-9 (ab69630) was purchased from Abcam. Control rabbit IgG (BA-1000) was purchased from Vector Labs. Goat-anti-Rabbit IgG-HRP was purchased from Dako. All antibodies were used per the manufacturer's recommendations.
Ex vivo phenotyping by flow cytometry
Nonadherent cells were stained with Fixable Viability Dyeefluor450 (1:1,000 in DPBS; eBioScience) for 30 minutes at 4 C. Cells were incubated 10 minutes in FcRg Block (eBioScience). For analysis of T-cell exhaustion, cells were split and stained with the following antibody combinations: (i) anti-CD3-Alexafluor700, anti-CD4-Fitc, anti-CD8, anti-PD-1, anti-TIM-3, anti-CD127, anti-CD27-APC-efluor780, and anti-CD69-biotin or (ii) anti-CD3-Alexafluor700, anti-CD4-APC-efluor780, anti-CD8, anti-PD-1, anti-TIM-3, and anti-LAG-3 for 25 minutes at 4 C. Anti-CD69-biotin was detected with Streptavidin-PE-TR (15 minutes at 4 C; eBioscience). Cells were resuspended in Â1 Fixation/with Â1 Permeabilization Buffer (eBioscience) and stained with either (i) anti-FoxP3 or (ii) anti-CTLA-4-biotin and anti-Ki67 (25 minutes at 4 C). Anti-CTLA-4-biotin was detected with Streptavidin-PE-TR (15 minutes at 4 C). For memory-cell marker analysis, cells were stained for CD3, CD8, PD-1, TIM-3, CD45RA, CD45RO, CD62L, CCR7, and intracellular perforin as described above. For PD-L1 expression analysis, adherent mDTC cells were stained with anti-EpCAM and anti-CD45 and either left unstained or stained with mIgG or anti-PD-L1 (25 minutes at 4 C). BCPAP, an adherent DTC cell line, was used as a positive control for both EpCAM and PD-L1. Stained cells were fixed in 2.5% paraformaldehyde (PFA; in PBS). Data were acquired using the Gallios 561 flow cytometer (Beckman Coulter). Ten-color compensation was achieved using mIgGk Compbeads (BD Bioscience). Data analysis was performed with FlowJo software (Tree Star, Inc.). Histogram overlays are displayed in unit area to compare populations containing a wide-range of events.
Stimulated cytokine production
Nonadherent cells were resuspended in media plus Golgi Plug (1:1,000; BD Biosciences) and plated at 2.0 Â 10 5 cells per well in a 96-well round-bottom plate. Cells were left unstimulated, stimulated with PMA (50 ng/mL; Sigma) plus ionomycin (0.5 mg/ mL; Sigma), or stimulated with plate-bound anti-CD3 (5 mg/mL) plus soluble anti-CD28 (2 mg/mL) and incubated for 6 hours (37 C/5.0% CO 2 ). Cells were harvested, incubated with Fixable Viability Dye, pretreated with FcRg block, and stained for CD3, CD4, CD8, PD-1, and TIM-3. Following fixation and permeabilization, cells were stained for intracellular IL2, IFNg, and TNFa (25 minutes at 4 C). Samples were fixed with 2.5% PFA and analyzed by flow cytometry.
Stimulated proliferation studies
Nonadherent cells were resuspended at 5 Â 10 6 cells/mL and loaded with 10 nmol/L 5-(and 6)-Carboxyfluorescein diacetate succinimidyl ester (CFSE; eBioscience) and were plated in media at 2.0 Â 10 5 cells/well in a 96-well round-bottom plate. Samples were stimulated with immobilized anti-CD3 (0.2 or 5 mg/mL) alone or in combination with soluble anti-CD28 (2 mg/mL) or with anti-CD3/anti-CD28 Dynabeads CTS (Life Technologies) at a 1:1 bead to cell ratio. Recombinant human IL2 was added to each well at 30 U/mL (eBioscience), and cells were incubated for 72 hours. Staining was performed for surface CD3, CD4, and CD8. Cells were fixed in 2.5% PFA and analyzed by flow cytometry.
Cytotoxic potential studies
Nonadherent cells were plated in media plus Golgi Plug (1:1,000) at 2.0 Â 10 5 cells/well in a 96-well round-bottom plate and left unstimulated or stimulated with PMA (50 ng/mL) plus ionomycin (0.5 mg/mL) for 4 hours. Anti-CD107a was added at the start of the incubation to detect CD107a within the extracellular membrane throughout the stimulation. Cells were harvested, incubated with Fixable Viability Dye, pretreated with FcRg block, and stained for CD3, CD4, CD8, PD-1, and TIM-3. Following fixation and permeabilization, cells were stained for intracellular perforin and IFNg (25 minutes at 4 C), fixed with 2.5% PFA, and analyzed by flow cytometry.
Galectin-9 expression analysis by immunohistochemistry
TILN specimens were chosen from each patient's archived tissues based on the presence of both overt metastases and tumor-associated lymphocytes. Tissue sections (4 mm) were deparaffinized and rehydrated. Antigen retrieval was performed in citrate buffer [10 mmol/L trisodium citrate (Sigma), 0.05% Tween-20 (Sigma), pH 6; 15 minutes, 110 C] in a Decloaking Chamber (Biocare Medical). Tissues were incubated with H 2 O 2 (3%; 30 minutes) followed by serum block (5% goat serum plus 1% BSA in DPBS; 1 hour) and stained with control rabbit IgG or anti-galectin-9 (4 mg/mL) overnight at 4 C. Anti-galectin-9 was detected with goat anti-rabbit-HRP and ImmPact Diaminobenzidine (DAB; Vector Labs). Tissues were counterstained with Mayer's hematoxylin (Sigma-Aldrich) and mounted with Cytoseal-XYL (Thermo Scientific). Staining intensity was scored on a 1 þ to 3 þ scale, and the percentage of positive cells was recorded. Allred scores were generated for comparison between samples (24).
Statistical analysis
To determine the statistical significance of interval data, we used the Mann-Whitney nonparametric, two-tailed t test. The level of statistical significance, with 95% confidence, was calculated and noted where P 0.05 ( Ã ) or P 0.01. To ensure statistical significance in our flow cytometry analyses (based on Poisson statistics), a minimum of 100 events were collected in the populations of interest.
Results
mDTC-associated PD-1
þ CD8 þ and CD4 þ T cells display a molecular profile indicative of exhaustion Clinical details of the 12 patients with mDTC are summarized in Table 1 . As shown in Fig. 1A CD69, suggesting that these lymph nodes were highly reactive despite the presence of advanced metastases. CD27 remained highly expressed by both PD-1
þ TILNs compared with that in normal lymph nodes (Fig. 1B) . Intracellular CTLA-4 was expressed at low levels by PD- (Fig. 2C ) or anti-CD3/anti-CD28 (Fig. 2D) . IFNg þ T cells frequencies were not significantly reduced in PD-
TILNs following PMA/ionomycin stimulation (Fig. 2E) ; however, the IFNg response was significantly lower when cells were stimulated with anti-CD3/anti-CD28 (Fig. 2F) . In line with our findings for IL2 and TNFa, IFNg production was maintained in patient 5 (Fig. 2F, arrows) . Cytokine production by CD4 þ T cells was comparable in PD-1 lo Tim-3 À and PD-1
TILNs following PMA/ionomycin stimulation (Fig. 2G) . Although a subset of PD-1 þ Tim-3 þ samples showed markedly reduced IL2 production following anti-CD3/anti-CD28 stimulation, a statistically significant difference was not observed (Fig. 2H) . Of note, cytokine production by patient peripheral blood T cells was variable but comparable between the PD-1 lo Tim-3 À and PD-1 Supplementary Fig. S3 ).
Cytokine levels were significantly lower in normal lymph nodes ( Supplementary Fig. S3 ) likely due to the high percentage of na€ ve T cells. Our comparison of PD-1 lo Tim-3 À and PD-1
TILNs suggests that expression of molecular markers of exhaustion was associated with impaired cytokine production by CD8 þ T cells. However, the degree of dysfunction was variable and did not occur in all patients or in tumor-associated PD-1
Proliferative potential is maintained in mDTC-associated CD8 þ and CD4 þ T cells
To determine whether mDTC-associated T cells were compromised in their proliferative capacity, we assessed Ki67 by flow T cells from patients 3, 5, 10, and 11 displayed a strong proliferative response that was only minimally reduced compared with peripheral blood-derived T cells (Fig. 3C) . A similar trend was Results were similar at lower bead:cell ratios (1:5 or 1:10) or in the absence of IL2 (data not shown). To interpret our results in the context of previous T-cell exhaustion studies in human cancers, we also assessed proliferation of mDTC-associated T cells from patient 11 in response to plate-bound anti-CD3 at low and high concentrations and anti-CD3 in combination with soluble anti-CD28 (Fig. 3C) . The low concentration of anti-CD3 was a weak stimulant, driving only one division in normal peripheral blood T cells after 3 days. Only 26% of CD4 þ T cells from patient 11 had divided. Of note, CD8 þ T cells were significantly reduced in number in both blood and TILN samples when stimulated with 0.2 mg/mL of anti-CD3 (data not shown). Under stronger stimulatory conditions (5 mg/ mL anti-CD3 and anti-CD3/anti-CD28), the proliferative response was slightly delayed in both CD8 þ and CD4 þ T cells from TILNs compared with those from control blood. Despite this delay, more than 96% of CD8 þ T cells and 60% of CD4 þ T cells had undergone at least one division by day 3. Thus, although mDTC-associated T cells were less responsive to suboptimal stimulation, proliferative capacity was largely preserved in response to moderate and strong stimuli ex vivo.
Cytotoxic potential may be compromised in CD8 þ T cells from
We next assessed the ability of mDTC-associated PD-1
þ T cells to degranulate. Ex vivo cytotoxic potential is commonly measured by CD107a mobilization to the cell surface (26) . As shown in Fig. 4A, 9 .5% of peripheral blood CD8 þ T cells had undergone degranulation following stimulation with PMA/ ionomycin. In line with this finding, 9.1% of peripheral blood CD8 þ T cells expressed intracellular perforin at baseline, and perforin expression was reduced to less than 1% following stimulation and exocytosis (Fig. 4B) . Sixteen percent to 49% of CD8 þ T cells from PD-1 þ Tim-3 þ samples (patients 10, 11, and 12) mobilized CD107a to the cell surface (Fig. 4A ). Of note, CD107a mobilization was most evident in the PD-1 þ and PD-
þ T-cell subsets in both peripheral blood and TILNs (Fig. 4A, column 3) . Surprisingly, mDTC-associated CD8 þ T cells showed no evidence of intracellular perforin (Fig. 4B) . As expected, perforin expression in peripheral blood CD8 þ T cells was confined to CD45RA þ CCR7 À T EMRA and, to a lesser extent, CD45RO þ CCR7 À T EM subsets ( Fig. 4C; ref. 25 ).
Perforin expression was absent in T EMRA (data not shown) and T EM (Fig. 4) in TILNs, regardless of PD-1 expression. These data suggest that although PD-1
degranulation, their cytotoxic potential may be diminished.
PD-L1 and galectin-9 are expressed by metastatic DTC PD-1 and Tim-3 inhibit T-cell function upon ligation of their requisite ligands, PD-L1 and galectin-9 (27) (28) (29) . As shown in Fig.  5 , we assessed PD-L1 expression by adherent cell populations derived from TILNs using flow cytometry. Tumor cells were identified by expression of epithelial-cell adhesion molecule (EpCAM; Fig. 5A ). BCPAP, a DTC cell line, displayed uniformly low expression of EpCAM but high expression of PD-L1. Primary tumor cells were readily distinguished by their high EpCAM expression, and 9 of 10 tumors expressed PD-L1 to varying degrees ( Fig. 5A and B) . No correlation was observed between PD-L1 expression levels and the frequency of PD-1 Fig. 5A and C) . In contrast, CD45 þ leukocytes from normal lymph nodes lacked PD-L1 expression (Fig. 5A ). As shown in Fig. 5D , galectin-9 was evident on both mDTC and tumorassociated leukocytes. Galectin-9 expression was similar between PD-1 lo Tim-3 À and PD-1 þ Tim-3 þ TILNs in both mDTC (6.1 AE 0.3 vs. 6.3 AE 0.5; P ¼ 0.8101) and leukocytes (5.9 AE 0.6 vs. 4.9 AE 1.1; P ¼ 0.1227; Supplementary Table S1 ). Leukocytes in normal lymph nodes stained at a similar intensity (Fig. 5D and Research. 
Discussion
Although PD-1 þ T cells have been found in association with many cancers, functional T-cell exhaustion has been characterized in only a subset of these studies (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . Here, we report variable defects in cytokine production by PD-1
from TILNs in patients with mDTC. Although T cells from patient 5 displayed a molecular profile of exhaustion, their ability to produce cytokines was unimpaired. Of note, the PD-1
tion. Although these data suggest that expression of multiple inhibitory receptors is necessary for reduced T-cell function, coexpression of PD-1 and Tim-3 by CD4 þ T cells (patients 2 and
3) did not confer a dysfunctional phenotype. Our data lend further support to the theory that expression of molecular markers of exhaustion (PD-1, Tim-3, CD69 hi , CD27 hi ) does not translate uniformly to impaired function (13, 33) . Viral and tumor models suggest that reduced cytotoxic potential occurs during the process of T-cell exhaustion. Specifically, reduced perforin expression was characteristic of exhausted CD8 þ T cells in chronic lymphocytic choriomeningitis virus infection (7). Furthermore, perforin was absent in melanoma-specific CD8 þ T cells from 6 of 9 TILNs (16). It is tempting to conclude that the lack of perforin expression in mDTC-associated CD8 þ T cells is another sign of functional exhaustion. However, our analysis revealed no evidence of perforin expression in normal lymph nodes (data not shown) or in the PD-1 À T EM population. Further analyses using reactive normal lymph node tissue and PD-1 lo Tim-3 À TILNs are required to determine whether the absence of perforin expression is due to tumor-induced T-cell exhaustion or inherent properties of lymph node tissue. Studies in other types of cancer have shown that expression of PD-1 and Tim-3 by tumor-associated T cells results in reduced proliferative capacity (10, 13, 17) . In follicular B-cell non-Hodgkin lymphoma, only 10% of Tim-3 þ
CD8
þ and 8% of Tim- following stimulation with anti-CD3 (5 mg/mL) and anti-CD28 (13) . In 7 of 20 CLL samples tested, the proportion of CD8 þ T cells that had undergone division was less than 25%. CD8 þ T-cell proliferation in the remaining 13 samples was similar to that observed in normal healthy controls. In our analyses using multiple stimulation regimens, we observed a subtle delay in T-cell proliferation in a subset of patients. However, more than 86% had undergone at least one division following anti-CD3/ anti-CD28 stimulation. This is in sharp contrast to the markedly reduced CD8 þ T-cell proliferative responses observed in CLL.
These data suggest that proliferative capacity is largely maintained in mDTC-associated T cells, despite enrichment of PD-1 (Table 1) . This paradox may be explained by the following hypotheses: (i) It is possible that, despite activation by professional antigen-presenting cells, tumors have escaped detection in these patients. High expression of CD69 by a significant portion of T cells in 3 of the 4 PD-1 lo Tim-3 À TILNs suggests that these cells have undergone activation. Given the extent of tumor load in these lymph nodes, it is probable that these activated T cells are reactive to the tumor rather than to unrelated pathogens. However, the tumor cells may have downregulated their own antigen processing and presentation machinery necessary for immune recognition.
(ii) T cells may be compromised (i.e., anergy and/or senescence) in vivo but not ex vivo. Functional defects may be reversed once the T cells are removed from the tumor microenvironment and exposed to nonphysiologic stimuli. In support of this hypothesis, Tregs, PD-L1, and galectin-9 were also evident in PD-1 lo Tim-3 À TILNs and likely encourage immune dysfunction. (iii) It is conceivable that T-cell exhaustion is a common theme in all TILNs but that signs of exhaustion are not evident in all samples at the time of analysis. Specifically, our characterization of PD-1 lo Tim-3 À TILNs may have taken place at the early stages of exhaustion where function is largely maintained and inhibitory receptors are not yet upregulated. It is likely that ex vivo restimulation with physiologically relevant antigen would reveal an even broader continuum of dysfunction among mDTC patients. Additional studies are required to characterize alternative mechanisms of T-cell dysfunction and tumor escape in mDTC.
As described above, regional mDTC appears to be slow-growing and poorly metastatic, but persists without elimination by the host immune system. Our studies suggest that, in the majority of patients with grossly involved lymph nodes, tumor-reactive T cells are actively engaging the tumor. Although ineffective in elimination, this response likely impedes tumor growth and metastases. The degree of functional exhaustion was variable in patients with evident PD-1 þ Tim-3 þ T-cell enrichment and may be reversible in the majority of cases. We suggest that immunomodulating therapies that inhibit PD-1/PD-L1 and/or Tim-3/galectin-9 are viable options for patients with persistent disease. These checkpoint therapies may also inhibit the suppressive activity of Tregs (34, 35) . Current PD-1/PD-L1-targeted therapies display low toxicities, and if injected locally into TILNs via ultrasound guidance, may be even more tolerable (36) (37) (38) . Although these studies focus on regional mDTC, we expect that PD-1/PD-L1-targeted therapies may be effective in patients with aggressive localized DTC and distant metastatic disease that cannot be cured by standard therapies [i.e., surgery, radioactive iodine, or tyrosine kinase inhibitors (TKI)]. The VEGFR2 inhibitor sorafenib was successful in slowing tumor growth, but did not achieve durable responses (39) . Future studies are necessary to characterize the immune response in aggressive DTC and to investigate the potential for PD-1/PD-L1 blockade and TKI combination therapy.
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